中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
11期
1635-1636
,共2页
尖吻蝮蛇血凝酶%耳鼻喉%术后%止血%安全性
尖吻蝮蛇血凝酶%耳鼻喉%術後%止血%安全性
첨문복사혈응매%이비후%술후%지혈%안전성
Acutus hemocoagulase%Otolaryngology%Post-operation%Stop-bleeding%Security
目的 评价耳鼻喉手术后使用尖吻蝮蛇血凝酶止血的安全性.方法 选取武装警察部队总医院2010年9-11月耳鼻喉科手术患者30例,术前及术中不予止血药,术后根据创面情况给予尖吻蝮蛇血凝酶静脉注射1～2U/次,1次/d,疗程1～3 d(使用前用1ml注射用水溶解).采用自身对照的研究方法,观察术前和术后第3天患者的凝血功能、血常规、肝肾功能、心电图等指标变化.结果 30例患者术前WBC(6.6±1.7)×109/L、RBC(4.6 ±0.6)×1012/L、Hb(142±18) g/L、PLT(219 ±44)× 109/L、PT(10.9±0.7)s、TT(17.1±0.9)s、APTT(27±3)s、FIB(2534±540) mg/L、ALT(26±17) U/L、TBIl(13±7)μmol/L、BUN(5.2±1.5) mmol/L、Cr(69±17) μmol/L;术后第3天WBC(7.8±3.0)×109/L、RBC(4.4±0.5)×1012/L、Hb(133±16) g/L、PLT(212±32)×109/L、PT(11.0±0.6)s、TT(16.0±1.9)s、APTT (26±3)s、FIB(2973±754) mg/L、ALT(22±12) U/L、TBIl(13±8)μmol/L、BUN(5.1±1.8) mmol/L、Cr(70±19) μmol/L.给药后与术前比较差异均无统计学意义(均P＞0.05).用药期间心电图未见特殊异常变化、无不良事件.结论 耳鼻喉手术后使用尖吻蝮蛇血凝酶减少创面渗血有较高的安全性.
目的 評價耳鼻喉手術後使用尖吻蝮蛇血凝酶止血的安全性.方法 選取武裝警察部隊總醫院2010年9-11月耳鼻喉科手術患者30例,術前及術中不予止血藥,術後根據創麵情況給予尖吻蝮蛇血凝酶靜脈註射1～2U/次,1次/d,療程1～3 d(使用前用1ml註射用水溶解).採用自身對照的研究方法,觀察術前和術後第3天患者的凝血功能、血常規、肝腎功能、心電圖等指標變化.結果 30例患者術前WBC(6.6±1.7)×109/L、RBC(4.6 ±0.6)×1012/L、Hb(142±18) g/L、PLT(219 ±44)× 109/L、PT(10.9±0.7)s、TT(17.1±0.9)s、APTT(27±3)s、FIB(2534±540) mg/L、ALT(26±17) U/L、TBIl(13±7)μmol/L、BUN(5.2±1.5) mmol/L、Cr(69±17) μmol/L;術後第3天WBC(7.8±3.0)×109/L、RBC(4.4±0.5)×1012/L、Hb(133±16) g/L、PLT(212±32)×109/L、PT(11.0±0.6)s、TT(16.0±1.9)s、APTT (26±3)s、FIB(2973±754) mg/L、ALT(22±12) U/L、TBIl(13±8)μmol/L、BUN(5.1±1.8) mmol/L、Cr(70±19) μmol/L.給藥後與術前比較差異均無統計學意義(均P＞0.05).用藥期間心電圖未見特殊異常變化、無不良事件.結論 耳鼻喉手術後使用尖吻蝮蛇血凝酶減少創麵滲血有較高的安全性.
목적 평개이비후수술후사용첨문복사혈응매지혈적안전성.방법 선취무장경찰부대총의원2010년9-11월이비후과수술환자30례,술전급술중불여지혈약,술후근거창면정황급여첨문복사혈응매정맥주사1～2U/차,1차/d,료정1～3 d(사용전용1ml주사용수용해).채용자신대조적연구방법,관찰술전화술후제3천환자적응혈공능、혈상규、간신공능、심전도등지표변화.결과 30례환자술전WBC(6.6±1.7)×109/L、RBC(4.6 ±0.6)×1012/L、Hb(142±18) g/L、PLT(219 ±44)× 109/L、PT(10.9±0.7)s、TT(17.1±0.9)s、APTT(27±3)s、FIB(2534±540) mg/L、ALT(26±17) U/L、TBIl(13±7)μmol/L、BUN(5.2±1.5) mmol/L、Cr(69±17) μmol/L;술후제3천WBC(7.8±3.0)×109/L、RBC(4.4±0.5)×1012/L、Hb(133±16) g/L、PLT(212±32)×109/L、PT(11.0±0.6)s、TT(16.0±1.9)s、APTT (26±3)s、FIB(2973±754) mg/L、ALT(22±12) U/L、TBIl(13±8)μmol/L、BUN(5.1±1.8) mmol/L、Cr(70±19) μmol/L.급약후여술전비교차이균무통계학의의(균P＞0.05).용약기간심전도미견특수이상변화、무불량사건.결론 이비후수술후사용첨문복사혈응매감소창면삼혈유교고적안전성.
Objective To evaluate the safety of hemocoagulase agkistrodon application after the otolaryngological operation.Methods Totally 30 patients with otolaryngology surgery in the Chinese People's Armed Police General Hospital from September 2010 to November 2010 were selected.They were not given hemostatic before operation and during operation.They were given haemocoagulase agkistrodon after operation according the bleeding situation,1-2 U one time for 1-3 days (dissolve 1 ml water for injection before using).The self-comparative method was used to observe the coagulation function,blood routine examination,liver and kidney function and ECG changes before operation and after surgery in 3 days.Results Two groups showed no significant differences in the coagulation parameters and safety indexes (all P ＞ 0.05).There were no adverse events occurring.Conclusion The application of haemocoagulase agkistrodon after otolaryngological operation is safe.
